medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Number 2

<< Back Next >>

Rev Invest Clin 2018; 70 (2)

Correlation between Lung and Joint Involvement in Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Cross-Sectional Study

Paulin F, Mercado JF, Fernández ME, Caro FM, Alberti ML, Fassola LA

Language: English
References: 33
Page: 76-81
PDF size: 76.32 Kb.


ABSTRACT

Background: Rheumatoid arthritis (RA) can affect the lungs in different manners, with interstitial lung disease (ILD) as the most serious manifestation. Although lung and joint compromise could be thought to evolve in parallel, there are data suggesting the opposite. In this study, we evaluated the relationship between lung and joint involvement in RA ILD. Methods: An observational cross-sectional study of RA ILD patients evaluated from January 2015 to February 2017. Joint disease assessment included number of tender and swollen joints, patient’s global assessment of disease activity, erythrocyte sedimentation rate (ESR) or C-reactive protein, and disease activity score (DAS28). Lung disease assessment included forced vital capacity, diffusion capacity (DLCO), and Goh high-resolution computed tomography (HRCT) score for total extent, ground glass, and reticular pattern. We studied the correlation between both components of the disease. Results: We included 46 patients, 14 (30.4%) men, with a mean (SD) of the age of 59.9 years (11.89). 12 (26.09) patients were in remission or had low disease activity measured with DAS28. The HRCT showed usual interstitial pneumonia (UIP) pattern in 10 (21.7%), possible UIP in 18 (39.1%), and inconsistent with UIP in 18 (39.1%). We found a good correlation between the ESR and the ground glass score in the HRCT (r = 0.39; p = 0.03). However, we found no correlation between lung function tests or HRCT scores and the other components of the DAS28. Conclusions: We only found a good correlation between ESR and ground glass score. It is possible that different pathways of the immune response mediate damage in lungs and joints.


REFERENCES

  1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269-81.

  2. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med. 1998;19:667-85, viii.

  3. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritisinterstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372-8.

  4. Restrepo JF, del Rincón I, Battafarano DF, et al. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol. 2015;34:1529-36.

  5. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232:81-91.

  6. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritisassociated interstitial lung disease: Radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270:583-8.

  7. Assayag D, Lee JS, King TE Jr. Rheumatoid arthritis associated interstitial lung disease: A review. Medicina (B Aires). 2014; 74:158-65.

  8. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322-8.

  9. Pérez-Dórame R, Mejía M, Mateos-Toledo H, Rojas-Serrano J. Rheumatoid arthritis-associated interstitial lung disease: Lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. Reumatol Clin. 2015;11:12-6.

  10. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases. Semin Arthritis Rheum. 2011; 41:256-64.

  11. Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B, et al. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med. 2015;30:104-9.

  12. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007;36:172-8.

  13. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British society for rheumatology biologics register. Ann Rheum Dis. 2010; 69:1086-91.

  14. Paulin F, Doyle TJ, Fletcher EA, Ascherman DP, Rosas IO. Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis: Shared mechanistic and phenotypic traits suggest overlapping disease mechanisms. Rev Invest Clin. 2015;67:280-6.

  15. Aletaha D, Neogi T, Silman AJ, et al 2010 rheumatoid arthritis classification criteria: An American college of rheumatology/ European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.

  16. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954-60.

  17. Singh JA, Furst DE, Bharat A, et al 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying Antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-39.

  18. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J. 2005;26:153-61.

  19. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

  20. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: A simple staging system Am J Respir Crit Care Med. 2008;177:1248-54.

  21. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology [STROBE] statement: Guidelines for reporting observational studies. Gac Sanit. 2008;22:144-50.

  22. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: A report from China. Rheumatol Int. 2012;32:669-73.

  23. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159-66.

  24. Fischer A, Solomon JJ, du Bois RM, Deane KD, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective Tissue disease. Respir Med. 2012;106:1040-7.

  25. Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009;28:611-3.

  26. Ye W, Fifield MC, Östör AJ. Refractory rheumatoid arthritis and associated interstitial lung disease: Could abatacept be the answer? J Clin Rheumatol. 2017;23:125-6.

  27. Wuyts WA, Cavazza A, Rossi G, et al. Differential diagnosis of usual interstitial pneumonia: When is it truly idiopathic? Eur Respir Rev. 2014;23:308-19.

  28. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus- associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006; 116:3183-94.

  29. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000;43:2619-33.

  30. Chatzidionisyou A, Catrina AI. The lung in rheumatoid arthritis, cause or consequence? Curr Opin Rheumatol. 2016;28:76-82.

  31. Paulin F, Babini A, Mamani M, Mercado J, Caro F. Practical approach to the evaluation and management of rheumatoid arthritis- interstitial lung disease based on its proven and hypothetical mechanisms. Rev Invest Clin. 2017;69:235-42.

  32. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: Evolution after treatment. Reumatol Clin. 2012;8:68-71.

  33. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thinsection CT for idiopathic pulmonary fibrosis: Correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169:977-83.




2020     |     www.medigraphic.com